Question 1

Am I eligible for this trial based on my current treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression clinical trial (NCT04209855). Contact the study team or your healthcare provider for specific answers.

Question 2

How does mirvetuximab soravtansine compare to the chemotherapy options I might receive?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression clinical trial (NCT04209855). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of mirvetuximab soravtansine compared to standard chemotherapy?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression clinical trial (NCT04209855). Contact the study team or your healthcare provider for specific answers.

Question 4

How often would I need to come in for treatment and monitoring if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression clinical trial (NCT04209855). Contact the study team or your healthcare provider for specific answers.

Question 5

What tests will be required to confirm my tumor's FRα expression?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression clinical trial (NCT04209855). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any additional costs or logistical considerations I should be aware of if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression clinical trial (NCT04209855). Contact the study team or your healthcare provider for specific answers.

What this study is about